(NASDAQ: IPSC) Century Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.37%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34%.
Century Therapeutics's earnings in 2026 is -$9,580,000.On average, 7 Wall Street analysts forecast IPSC's earnings for 2026 to be -$115,489,839, with the lowest IPSC earnings forecast at -$176,128,295, and the highest IPSC earnings forecast at -$73,596,466. On average, 7 Wall Street analysts forecast IPSC's earnings for 2027 to be -$101,920,772, with the lowest IPSC earnings forecast at -$156,754,183, and the highest IPSC earnings forecast at -$62,273,933.
In 2028, IPSC is forecast to generate -$92,880,717 in earnings, with the lowest earnings forecast at -$132,096,221 and the highest earnings forecast at -$60,386,844.